Kidney cancer treatments under the microscope: real-world data from 327 patients
NCT ID NCT06345183
First seen Nov 06, 2025 · Last updated May 19, 2026 · Updated 27 times
Summary
This study looked at medical records from 327 adults with advanced kidney cancer to see how two drug combinations (nivolumab plus ipilimumab or pembrolizumab plus lenvatinib) are used in everyday U.S. clinics. Researchers collected information on patient backgrounds, treatment details, and outcomes. The goal was to describe real-world patterns, not to test new treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED RENAL CELL CARCINOMA (ARCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cardinal Health
Dublin, Ohio, 43017, United States
Conditions
Explore the condition pages connected to this study.